Comparing 36 vs 38 Hour Intervals for Oocyte Pick-Up in IVF

Does Time From Ovulation Trigger To Oocyte Pick-Up Affect Intracytoplasmic Sperm Injection Outcomes? A Multi-Center Single-Blinded Randomized Controlled Trial Comparing 36 and 38 Hour Intervals

This study is testing whether waiting 36 or 38 hours after an ovulation trigger before collecting eggs can lead to better results for women undergoing IVF.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 850 (estimated)
• Ages: 18 Years to 42 Years
• Sex: Female
• Sponsor: Koç University (other)
• Locations: 7 sites (Adana and 6 other locations)
• Trial ID: NCT05803655 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the outcomes of assisted reproductive technology (ART) by comparing two different time intervals (36 hours vs 38 hours) between ovulation trigger and oocyte pick-up (OPU) in women undergoing IVF. Participants will be randomly assigned to one of the two groups after providing informed consent. The study will assess various outcomes, including the ratio of mature oocytes, fertilization rates, and pregnancy outcomes. The trial is conducted across multiple centers to ensure a diverse patient population.

Who should consider this trial

Good fit: Ideal candidates are women aged 18-42 undergoing ART treatment and planning for embryo transfer within six months of oocyte collection.

Not a fit: Patients with a body mass index of 35 kg/m2 or above, systemic diseases affecting ART outcomes, or congenital uterine anomalies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could optimize the timing of oocyte pick-up, potentially improving IVF success rates for patients.

How similar studies have performed: Previous studies have explored similar timing strategies in IVF, showing varying results, but this specific comparison of 36 vs 38 hours is novel.

Eligibility criteria

Inclusion Criteria:

* To undergo assisted reproductive technology (ART) treatment and planning to undergo embryo transfer procedure within 6 months of oocyte collection
* Female partner to be between 18-42 years old at the time of informed consent
* Both partners to consent to participate in the study and be legally eligible to give consent.

Exclusion Criteria:

* Female partner to have participated in the study previously.
* Female partner to have a body mass index of 35 kg/m2 or above.
* Female partner to have a systemic disease that may affect ART or pregnancy outcomes (e.g. antiphospholipid syndrome, severe liver dysfunction, diabetes mellitus, history of venous thrombosis, advanced renal or cardiac diseases).
* Presence of congenital uterine anomaly (1-Women whose uterine anomalies are surgically corrected are not excluded; 2- Arcuate uterus is not accepted as a congenital uterine anomaly).
* Presence of submucous or intramural fibroid that distorts the endometrial cavity.
* Diagnosis of stage 3 or 4 endometriosis in the female partner.
* Female partner planned to undergo double ovarian stimulation.
* Known karyotype anomaly in at least one of the partners.
* Diagnosis of azoospermia (no sperm cells in the ejaculate) in the male partner.
* History of recurrent implantation failure \[defined according to the scoring system by Ata et al in 2021 available at https://bit.ly/3huVLOn (Ata B, Kalafat E, Somigliana E. A new definition of recurrent implantation failure on the basis of anticipated blastocyst aneuploidy rates across female age. Fertil Steril. 2021;116(5):1320-1327. doi:10.1016/j.fertnstert.2021.06.045\].
* History of recurrent pregnancy loss \[defined as a history of 2 or more biochemical/clinical pregnancy losses, in accordance with the European Society of Human Reproduction and Embryology(ESHRE) Guideline on the management of recurrent pregnancy loss issued on 1 February 2023, available at https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx\].

Where this trial is running

Adana and 6 other locations

• Baskent University — Adana, Turkey (RECRUITING)
• Ankara University — Ankara, Turkey (RECRUITING)
• Hacettepe University — Ankara, Turkey (RECRUITING)
• Uludag University — Bursa, Turkey (RECRUITING)
• Koc University — Istanbul, Turkey (RECRUITING)
• Bahceci Fulya IVF Centre — Istanbul, Turkey (RECRUITING)
• VKF American Hospital — Istanbul, Turkey (RECRUITING)

Study contacts

• Principal investigator: Engin Turkgeldi, Assoc. Prof — Koç University
• Study coordinator: Engin Turkgeldi, Assoc.Prof.

Conditions: Infertility, IVF, oocyte pick-up, in vitro fertilization, oocyte maturation, ovulation trigger, intracytoplasmic sperm injection